# Safety, Tolerability and Immunogenicity of a Maternal Respiratory Syncytial Virus (RSV) Vaccine (MKK900) in Healthy Adult Women

> **NCT07492706** · PHASE1 · NOT_YET_RECRUITING · sponsor: **MAXVAX Biotechnology Limited Liability Company** · enrollment: 120 (estimated)

## Conditions studied

- Respiratory Syncytial Virus (RSV)

## Interventions

- **BIOLOGICAL:** MKK900 60 µg
- **BIOLOGICAL:** MKK900 120 µg
- **BIOLOGICAL:** ABRYSVO®

## Key facts

- **NCT ID:** NCT07492706
- **Lead sponsor:** MAXVAX Biotechnology Limited Liability Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04-01
- **Primary completion:** 2026-04-30
- **Final completion:** 2027-01-15
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2026-03-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07492706

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07492706, "Safety, Tolerability and Immunogenicity of a Maternal Respiratory Syncytial Virus (RSV) Vaccine (MKK900) in Healthy Adult Women". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT07492706. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*